LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

LLY

1,093.51

-3.35%↓

JNJ

225.48

-2.31%↓

ABBV

215.94

-1.07%↓

UNH

380.86

-0.12%↓

MRK

119.64

+0.1%↑

Inicio・Lista de Acciones・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Abierto

SectorSanidad

35.58 -2.31

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

34.69

Máximo

36.49

Métricas clave
By Trading Economics
Ingresos	-5M -128M
Ventas	6.8M 11M
BPA	-1.23
Margen de beneficios	-1,191.029
Empleados	594
EBITDA	-18M -139M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+132.4% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-469M 3.9B
Apertura anterior	37.89
Cierre anterior	35.58

Noticias sobre sentimiento de mercado

By Acuity

50%

156 / 344 Clasificación en Healthcare

Crinetics Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 may 2026, 22:47 UTC

Ganancias

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 may 2026, 20:45 UTC

Ganancias

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 may 2026, 23:39 UTC

Charlas de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 may 2026, 23:31 UTC

Charlas de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 may 2026, 23:17 UTC

Charlas de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 may 2026, 23:02 UTC

Charlas de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 may 2026, 22:37 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 may 2026, 21:12 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 may 2026, 21:00 UTC

Ganancias

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 may 2026, 20:57 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:55 UTC

Ganancias

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

28 may 2026, 20:48 UTC

Acciones populares

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 may 2026, 20:34 UTC

Ganancias

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 may 2026, 20:31 UTC

Ganancias

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 may 2026, 20:28 UTC

Ganancias

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 may 2026, 20:26 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Membership Fees $1.37B

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Net Sales $69.15B

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparación entre iguales

Cambio de precio

Crinetics Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

132.4% repunte

Estimación a 12 Meses

Media 85.5 USD 132.4%

Máximo 97 USD

Mínimo 67 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

156 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.